Conţinutul numărului revistei |
Articolul precedent |
Articolul urmator |
1119 12 |
Ultima descărcare din IBN: 2023-07-04 13:54 |
SM ISO690:2012 BACINSCHI, Nicolae, GHICAVÂI, Victor, BALTAG, Natalia, BACINSCHI, Aurelia, MORNEALA, Elena. Realizări şi perspective în tratamentul diabetului zanarat tip . In: Analele Ştiinţifice ale USMF „N. Testemiţanu”, 2012, nr. 1(13), pp. 187-195. ISSN 1857-1719. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Analele Ştiinţifice ale USMF „N. Testemiţanu” | ||||||
Numărul 1(13) / 2012 / ISSN 1857-1719 | ||||||
|
||||||
Pag. 187-195 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
The realisations and perspectives in diabetes mellitus treatment
The rational selection of oral antidiabetics in diabetes mellitus treatment, type II is determined by the influence upon pathogenic way, prevention of insulinoresistance and insulin secretion insufficiency. With this purpose theare can be utilized sulphonylureics (glyclazide, glypizide, glymepiride etc.), biguanides (metphormine), meglytinedes (repaglynide, nateglynide, mitiglynide), thyazolidindiones (pioglytazone, balaglyztazone, rivoglitazone etc.), dual/pan PPAR modulators ( tesaglitazar, muraglitazar, aleglitazar, chiglitazar etc.), tetrazaharides (acarboze, vogliboze etc.), GLP-1 agonists (exenatide, exenatide LAR, liraglutide, albiglutide etc.), DPP-IV antagonists and blockers (sitaglypide, vildaglyptide, saxaglyptine, aloglyptine), amilines analogues (pramlintid), selective sodium glucose cotransporter-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin etc.), 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors (INCB13739), situins (resveratrol etc.), AMP-activated protein kinase (imeglimin etc.), glucokinase activators (piragliatin etc.), agonists D2-receptors (bromcriptine), bile acid sequestrants (coleselevam) etc.. |
||||||
|
Cerif XML Export
<?xml version='1.0' encoding='utf-8'?> <CERIF xmlns='urn:xmlns:org:eurocris:cerif-1.5-1' xsi:schemaLocation='urn:xmlns:org:eurocris:cerif-1.5-1 http://www.eurocris.org/Uploads/Web%20pages/CERIF-1.5/CERIF_1.5_1.xsd' xmlns:xsi='http://www.w3.org/2001/XMLSchema-instance' release='1.5' date='2012-10-07' sourceDatabase='Output Profile'> <cfResPubl> <cfResPublId>ibn-ResPubl-18113</cfResPublId> <cfResPublDate>2012-02-01</cfResPublDate> <cfVol>13</cfVol> <cfIssue>1</cfIssue> <cfStartPage>187</cfStartPage> <cfISSN>1857-1719</cfISSN> <cfURI>https://ibn.idsi.md/ro/vizualizare_articol/18113</cfURI> <cfTitle cfLangCode='RO' cfTrans='o'>Realizări şi perspective în tratamentul diabetului zanarat tip </cfTitle> <cfAbstr cfLangCode='EN' cfTrans='o'>The realisations and perspectives in diabetes mellitus treatment The rational selection of oral antidiabetics in diabetes mellitus treatment, type II is determined by the influence upon pathogenic way, prevention of insulinoresistance and insulin secretion insufficiency. With this purpose theare can be utilized sulphonylureics (glyclazide, glypizide, glymepiride etc.), biguanides (metphormine), meglytinedes (repaglynide, nateglynide, mitiglynide), thyazolidindiones (pioglytazone, balaglyztazone, rivoglitazone etc.), dual/pan PPAR modulators ( tesaglitazar, muraglitazar, aleglitazar, chiglitazar etc.), tetrazaharides (acarboze, vogliboze etc.), GLP-1 agonists (exenatide, exenatide LAR, liraglutide, albiglutide etc.), DPP-IV antagonists and blockers (sitaglypide, vildaglyptide, saxaglyptine, aloglyptine), amilines analogues (pramlintid), selective sodium glucose cotransporter-2 inhibitors (dapagliflozin, canagliflozin, empagliflozin etc.), 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors (INCB13739), situins (resveratrol etc.), AMP-activated protein kinase (imeglimin etc.), glucokinase activators (piragliatin etc.), agonists D2-receptors (bromcriptine), bile acid sequestrants (coleselevam) etc..</cfAbstr> <cfAbstr cfLangCode='RO' cfTrans='o'>Selectarea raţională a antidiabeticelor orale în tratamentul diabetului zaharat tip 2 este determinată de influenţa asupra verigelor patogenetice, combaterea insulinorezistenţei şi insuficienţei secreţiei insulinei. Cu acest svop se pot utiliza: sulfonilureicele (gliclazida, glipizida, glimepirida etc.), biguanidele (metformina), meglitinidele (repaglinida, nateglinida, mitiglinida), tiazolidindionele (pioglitazon, balaglitazon, rivoglitazon etc.), modulatorii bi-şi pan ai PPAR receptorilor (tesaglitazar, muraglitazar, aleglitazar, cicglitazar etc.), tetrazaharidele (acarboza, vogliboza etc.), agoniştii GLP-1 (exenatid, exenatid LAR, liraglutid, albiglutid etc.), antagoniştii sau blocantele DPP-IV (sitagliptina, vildagliptina, saxagliptina, alogliptina etc.), analogii amilinei (pramlintid), inhibitorii sodiu-glucoză cotransportorului 2 (dalagliflozin, canagliflozin, empagliflozin etc.), inhibitorii 11-beta-hidroxisteroid dehidrogenazei 1 (INCB13739), sirtuinele (resveratrol etc.), activatorii AMP-protein kinazei (imeglimin etc.), activatorii glucokinazei (piragliatin etc.), agoniştii D2-receptorilor (bromocriptina etc.), sechestranţii acizilor biliari (coleselevam etc.) etc..</cfAbstr> <cfResPubl_Class> <cfClassId>eda2d9e9-34c5-11e1-b86c-0800200c9a66</cfClassId> <cfClassSchemeId>759af938-34ae-11e1-b86c-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfResPubl_Class> <cfClassId>e601872f-4b7e-4d88-929f-7df027b226c9</cfClassId> <cfClassSchemeId>40e90e2f-446d-460a-98e5-5dce57550c48</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfResPubl_Class> <cfPers_ResPubl> <cfPersId>ibn-person-10648</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-11721</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-18769</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-33883</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> <cfPers_ResPubl> <cfPersId>ibn-person-31661</cfPersId> <cfClassId>49815870-1cfe-11e1-8bc2-0800200c9a66</cfClassId> <cfClassSchemeId>b7135ad0-1d00-11e1-8bc2-0800200c9a66</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> </cfPers_ResPubl> </cfResPubl> <cfPers> <cfPersId>ibn-Pers-10648</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-10648-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Bachinsky</cfFamilyNames> <cfFirstNames>N.G.</cfFirstNames> <cfFamilyNames>Бачинский</cfFamilyNames> <cfFirstNames>Николай</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-11721</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-11721-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Ghicavîi</cfFamilyNames> <cfFirstNames>Victor</cfFirstNames> <cfFamilyNames>Гикавый</cfFamilyNames> <cfFirstNames>Виктор</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-18769</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-18769-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Baltag</cfFamilyNames> <cfFirstNames>Natalia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-33883</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-33883-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Bacinschi</cfFamilyNames> <cfFirstNames>Aurelia</cfFirstNames> </cfPersName_Pers> </cfPers> <cfPers> <cfPersId>ibn-Pers-31661</cfPersId> <cfPersName_Pers> <cfPersNameId>ibn-PersName-31661-2</cfPersNameId> <cfClassId>55f90543-d631-42eb-8d47-d8d9266cbb26</cfClassId> <cfClassSchemeId>7375609d-cfa6-45ce-a803-75de69abe21f</cfClassSchemeId> <cfStartDate>2012-02-01T24:00:00</cfStartDate> <cfFamilyNames>Morneala</cfFamilyNames> <cfFirstNames>Elena</cfFirstNames> </cfPersName_Pers> </cfPers> </CERIF>